Revolutionizing Breast Cancer Treatment: Harnessing Ehrlich Ascites Carcinoma Model, Cancer Metabolism, and Nanotechnology-Enhanced Chemotherapy for Improved Patient Outcomes.

A model known as Ehrlich ascites carcinoma (EAC) was developed to study breast cancer, which is predicted to be among the most prevalent cancers in women globally. Normally, the glycolysis pathway is supported by mitochondria to generate the energy required for cell survival. Therefore, pharmacological drugs that inhibit mitochondrial pyruvate dehydrogenase kinase (PDK) may offer an appealing new avenue for cancer treatment. Dichloroacetate (DCA) is a chemotherapeutic drug with anticancer properties. Dichloro-acetate nanoformulations (DCANPs) are becoming a growing trend in medicine because of their enhanced bioavailability, penetration capability, and potency. Polyvinyl alcohol (PVA) and poly- (lactic-co-glycolic acid) (PLGA) are highly flexible and adaptive polymer combinations. Both polymers offer advantages such as stability, sustainability, high adsorption capacity, biocompatibility, and adhesive properties. They also affect permeability and can form small spheres. DCANPs may be an effective therapeutic choice for the treatment of Ehrlich ascites carcinoma (EAC) because they inhibit pyruvate dehydrogenase kinase (PDK).